PEOPLE - US FDA appoints principal deputy commissioner and chief scientist
This article was originally published in Clinica
The US FDA (Rockville, Maryland) has appointed Frank Torti as principal deputy commissioner and chief scientist, effective from May 2008. The newly-created role of chief scientist is to "ensure that the foundation of the FDA's regulatory structure will always be state-of-the-art science," said Andrew von Eschenbach, commissioner of food and drugs. Dr Torti, a "prominent clinician scientist and researcher in molecular oncology", is currently chair of the department of cancer biology and director of the comprehensive cancer centre at Wake Forest University School of Medicine (Winston-Salem, New Carolina).
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.